DEFA14A: Opus Genetics Urges Stockholders to Vote FOR Board Nominees Amidst Contentious Proxy Battle

Opus Genetics files its definitive proxy statement and urges stockholders to vote for its board nominees, highlighting the company's transformation and progress while criticizing a campaign by former CEO Mina Sooch to replace a majority of directors.

Summary

• Opus Genetics has mailed its definitive proxy materials to stockholders for the upcoming 2025 Annual Meeting on April 30, 2025.
• The board encourages stockholders to vote FOR all nine of Opus' nominees on the BLUE proxy card.
• The company highlights its transformation over the past two years, including the acquisition of Legacy Opus and the appointment of a new leadership team.
• A key proposal at the Annual Meeting is the conversion of preferred shares into common shares to unify the capital structure.
• Former CEO Mina Sooch is attempting to replace a majority of the board with her own nominees.
• Opus' board believes Sooch's nominees lack relevant experience and that her proposed strategy is not in the best interests of stockholders.
• The company recently raised $21.5 million in capital from healthcare investors.
• Stockholders are encouraged to contact Sodali & Co. for assistance with voting.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While highlighting positive developments like the acquisition and capital raise, it also addresses the challenges posed by the proxy battle and the need for stockholder support. The overall tone is cautiously optimistic.

Positives

• Opus Genetics has revitalized its portfolio with promising gene therapy assets targeting inherited retinal diseases (IRDs).
• The company has appointed a new leadership team with extensive business, financial, and medical expertise.
• The board has been strengthened with the addition of three experienced directors.
• Opus has secured $21.5 million in capital from top-tier healthcare investors.
• The company has a defined regulatory pathway for its gene therapy assets, potentially leading to nearer-term clinical milestones.

Negatives

• Former CEO Mina Sooch is leading a proxy battle to replace a majority of the board.
• The company's previous lead asset, APX3330, failed to meet its primary endpoint in a Phase 2 clinical trial.
• The company's out-licensed Phentolomine Ophthalmic Solution program has generated modest sales to date.
• The company faces potential disruption and uncertainty due to the proxy contest.

Risks

• The company's ability to successfully integrate the business of former Opus Genetics Inc. and manage its expanded combined product pipeline.
• The company's ability to develop and obtain regulatory approval for newly acquired gene therapies to treat inherited retinal diseases.
• The success and timing of regulatory submissions and pre-clinical and clinical trials, including enrollment and data readouts.
• The company's ability to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs.
• Actions by activist stockholders.

Future Outlook

Opus Genetics believes it is well-positioned for the future with a new leadership team, a compelling strategy, a strengthened pipeline, and a refreshed Board. The company aims to advance its new plan with a unified capital structure.

Management Comments

• The Board has worked diligently to reposition the Company and set it on a path for success.
• The new management team, with the Board's oversight, conducted a review of Ocuphire's assets and strategy.
• We do not believe Ms. Sooch's strategy is in the best interests of stockholders, and, in our view, the election of Ms. Sooch's nominees would take Opus backward.

Industry Context

Opus Genetics' focus on gene therapies for inherited retinal diseases aligns with a growing trend in the biotechnology industry towards developing targeted therapies for genetic disorders. The company's acquisition of Legacy Opus and its pipeline of gene therapies positions it to compete in the ophthalmic biotechnology market.

Comparison to Industry Standards

• Companies like Spark Therapeutics (now part of Roche) and REGENXBIO are key players in the gene therapy space, particularly for inherited retinal diseases.
• Spark Therapeutics' Luxturna, the first FDA-approved gene therapy for an inherited disease, serves as a benchmark for regulatory approval and commercialization in this field.
• REGENXBIO's AAV-based gene therapy platform is widely used in the development of treatments for various genetic disorders, including ophthalmic conditions.
• Opus Genetics' focus on IRDs and its recent capital raise suggest a commitment to competing with these established players in the gene therapy market.

Management Changes

Stakeholder Impact

• Shareholders are impacted by the proposed changes to the board and the company's strategic direction.
• Employees are affected by the changes in leadership and the company's focus on gene therapy.
• Patients with inherited retinal diseases stand to benefit from the development of new gene therapies.
• The outcome of the proxy battle could impact the company's relationships with its suppliers and partners.

Next Steps

• Stockholders need to vote on the proposals outlined in the proxy statement.
• The Annual Meeting will be held on April 30, 2025.
• The company will continue to advance its pipeline of gene therapy assets.

Key Dates

Keywords

Opus Genetics, proxy statement, Annual Meeting, Mina Sooch, board of directors, gene therapy, inherited retinal diseases, IRD, stockholders, proxy battle